Sign In
Buy OTLK
$0.98
-0.0634 (-6.10%)
At Close: Jul 31, 2026
U.S. stock futures rose on the first trading day of the year on Friday after missing the Santa Claus rally over the truncated week. Futures of major benchmark indices were higher. The Santa Claus trad
Apple, Taiwan Semiconductor Manufacturing And 3 Stocks To Watch Heading Into Friday
02:19am, Friday, 02'nd Jan 2026
U.S. stock futures up, Apple reduces Vision Pro production, TSMC gets U.S. export license, VS Media announces share combination.
Oncobiologics, Inc. (NASDAQ:OTLK) Receives Consensus Rating of “Hold” from Analysts
01:23am, Friday, 02'nd Jan 2026
Oncobiologics, Inc. (NASDAQ: OTLK - Get Free Report) has been assigned an average rating of "Hold" from the six analysts that are covering the firm, Marketbeat reports. One equities research analyst h
US FDA declines to approve Outlook Therapeutics' eye disease drug
04:23pm, Wednesday, 31'st Dec 2025
The U.S. Food and Drug Administration has declined to approve Outlook Therapeutics' drug for a type of eye disease, the company said on Wednesday, marking another setback to its prolonged effort to br
FDA issues Complete Response Letter (CRL) for resubmitted ONS-5010 BLA FDA issues Complete Response Letter (CRL) for resubmitted ONS-5010 BLA
Third Time's The Charm: Outlook Therapeutics Lytenava Heads To FDA, Again
08:08pm, Sunday, 28'th Dec 2025
Outlook Therapeutics (OTLK) faces a pivotal FDA decision for Lytenava on December 31st, following two prior rejections and a 2025 recovery in share price. My bullish stance is underpinned by the NORSE
Outlook Therapeutics Announces New Employment Inducement Grants
05:00pm, Friday, 26'th Dec 2025
ISELIN, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of re
Oncobiologics, Inc. (OTLK) Reports Q4 Loss, Lags Revenue Estimates
10:31am, Friday, 19'th Dec 2025
Oncobiologics, Inc. (OTLK) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.77 per share a year ago.
Outlook Therapeutics Reports Financial Results for Fiscal Year 2025
08:05am, Friday, 19'th Dec 2025
ISELIN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of re
Contrasting Barinthus Biotherapeutics (NASDAQ:BRNS) & Oncobiologics (NASDAQ:OTLK)
02:00am, Thursday, 11'th Dec 2025
Oncobiologics (NASDAQ: OTLK - Get Free Report) and Barinthus Biotherapeutics (NASDAQ: BRNS - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the
Oncobiologics, Inc. (NASDAQ:OTLK) Given Average Rating of “Hold” by Analysts
01:10am, Monday, 08'th Dec 2025
Shares of Oncobiologics, Inc. (NASDAQ: OTLK - Get Free Report) have been given an average rating of "Hold" by the six brokerages that are currently covering the stock, Marketbeat reports. One investme
Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
09:05am, Monday, 24'th Nov 2025
ISELIN, N.J., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of re
Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
08:30am, Thursday, 13'th Nov 2025
ISELIN, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of re
Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010
08:35am, Monday, 03'rd Nov 2025
ISELIN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of r
Outlook Therapeutics Provides Update on Type A Meeting with FDA
08:45am, Monday, 29'th Sep 2025
ISELIN, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment o
